0 646

Cited 7 times in

A Feasibility Study Using Three-dimensional Conformal Boost Technique in Locally Advanced Carcinoma of the Nasopharynx

DC Field Value Language
dc.contributor.author김귀언-
dc.contributor.author성진실-
dc.contributor.author이창걸-
dc.date.accessioned2016-02-19T11:05:05Z-
dc.date.available2016-02-19T11:05:05Z-
dc.date.issued2001-
dc.identifier.issn0284-186X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/142360-
dc.description.abstractTo investigate the feasibility and efficacy of dose escalation using three-dimensional (3-D) conformal boost technique, 21 patients with stage III or IV nasopharyngeal cancer were enrolled in a prospective protocol. All patients with node metastases initially received external radiotherapy by conventional technique up to 70.2 Gy, followed by 3-D conformal radiotherapy (3-D CRT) to the boost part up to 79.2 Gy with 9 Gy increments (daily fraction of 1.8 Gy for 5 days). A modified technique with the same dose escalation of 9 Gy using 3-D CRT was applied to 7 patients without node metastases, who were treated by conventional technique up to 54 Gy, followed by 3-D CRT to boost up to a basic dose of 70.2 Gy, and then finally with dose escalation of 9 Gy. The protocol was relatively well tolerated by the majority of patients. Acute complications during the dose escalation schedule was low, with rare occurrences of grade 3 or 4 toxicity. Although late radiation-induced complications also appeared limited, 1 patient developed a temporal lobe necrosis and 2 patients suffered from sensory-neural hearing loss. There were no radiation-induced fatal complications. At a median follow-up of 48 months, only 3 patients experienced local failure and 2 patients developed distant metastases. The 5-year overall actuarial survival rate and recurrencefree survival rate for all patients were 68% and 85%, respectively. On the basis of acceptable morbidity and encouraging treatment results, we conclude that the dose escalation in 9 Gy increments using a 3-D conformal boost technique is relatively safe and efficacious, enough to be used routinely for locally advanced nasopharyngeal cancers.-
dc.description.statementOfResponsibilityopen-
dc.format.extent582~587-
dc.relation.isPartOfACTA ONCOLOGICA-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCarcinoma/mortality-
dc.subject.MESHCarcinoma/pathology-
dc.subject.MESHCarcinoma/radiotherapy*-
dc.subject.MESHCavernous Sinus/pathology-
dc.subject.MESHCranial Nerve Diseases/etiology-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFeasibility Studies-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHematologic Diseases/etiology-
dc.subject.MESHHumans-
dc.subject.MESHLife Tables-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNasopharyngeal Neoplasms/mortality-
dc.subject.MESHNasopharyngeal Neoplasms/pathology-
dc.subject.MESHNasopharyngeal Neoplasms/radiotherapy*-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHProspective Studies-
dc.subject.MESHRadiation Injuries/etiology-
dc.subject.MESHRadiodermatitis/etiology-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRadiotherapy, Conformal/adverse effects-
dc.subject.MESHRadiotherapy, Conformal/methods*-
dc.subject.MESHSkull Base/pathology-
dc.subject.MESHStomatitis/etiology-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHXerostomia/etiology-
dc.titleA Feasibility Study Using Three-dimensional Conformal Boost Technique in Locally Advanced Carcinoma of the Nasopharynx-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorGwi Eon Kim-
dc.contributor.googleauthorJihoon Lim-
dc.contributor.googleauthorHee Chul Park-
dc.contributor.googleauthorKi Chang Keum-
dc.contributor.googleauthorYong Bae Kim-
dc.contributor.googleauthorSun Rock Moon-
dc.contributor.googleauthorChang Geol Lee-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorChang Ok Suh-
dc.identifier.doi10.1080/028418601750444114-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00321-
dc.contributor.localIdA01956-
dc.contributor.localIdA03240-
dc.relation.journalcodeJ00024-
dc.identifier.eissn1651-226X-
dc.identifier.pmid11669329-
dc.identifier.urlhttp://informahealthcare.com/doi/abs/10.1080/028418601750444114-
dc.contributor.alternativeNameKim, Gwi Eon-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameLee, Chang Geol-
dc.contributor.affiliatedAuthorKim, Gwi Eon-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorLee, Chang Geol-
dc.rights.accessRightsnot free-
dc.citation.volume40-
dc.citation.number5-
dc.citation.startPage582-
dc.citation.endPage587-
dc.identifier.bibliographicCitationACTA ONCOLOGICA, Vol.40(5) : 582-587, 2001-
dc.identifier.rimsid30942-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.